Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12768700 | 0.88 | PDE5A (0.55) | PDE5AKCNH2 | |
| SCHEMBL12768704 | 0.85 | PDE5A (0.56) | PDE5AKCNH2 | |
| SCHEMBL4701111 | 0.81 | PDE5A (0.68) | PDE5AKCNH2 | |
| SCHEMBL12768668 | 0.81 | PDE5A (0.48) | PDE5AKCNH2 | |
| SCHEMBL4703074 | 0.81 | PDE5A (0.61) | PDE5AKCNH2 | |
| SCHEMBL4040505 | 0.80 | PDE5A (0.57) | PDE5AKCNH2 | |
| SCHEMBL12768599 | 0.80 | PDE5A (0.64) | PDE5AKCNH2 | |
| SCHEMBL12768844 | 0.79 | PDE5A (0.84) | PDE5AKCNH2 | |
| SCHEMBL4701226 | 0.77 | PDE5A (0.61) | PDE5AKCNH2 | |
| SCHEMBL8242984 | 0.76 | PDE5A (0.67) | PDE5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518956-B2 | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl) piperidine-4-carboxylic acid and salts thereof | PHARMACIA & UPJOHN COMPANY LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518956-B2 | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl) piperidine-4-carboxylic acid and salts thereof | PHARMACIA & UPJOHN COMPANY LLC (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110059993-A1 | 1-(1-(2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino)-1H-Pyrazolo[4,3-D]Pyrimidin-5-YL) Piperidine-4-Carboxylic Acid And Salts Thereof | PFIZER INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059993-A1 | 1-(1-(2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino)-1H-Pyrazolo[4,3-D]Pyrimidin-5-YL) Piperidine-4-Carboxylic Acid And Salts Thereof | PFIZER INC. | 2011-03-10 | — | — | US | disclosed |
| US-20090156618-A1 | 1-(1- (2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino) - 1H-Pyrazolo [4,3-D] Pyrimidin-5-YL) Piperidine-4-Carboxylic acid and salts thereof | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
| US-20090156618-A1 | 1-(1- (2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino) - 1H-Pyrazolo [4,3-D] Pyrimidin-5-YL) Piperidine-4-Carboxylic acid and salts thereof | PFIZER INC | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059993-A1 | 1-(1-(2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino)-1H-Pyrazolo[4,3-D]Pyrimidin-5-YL) Piperidine-4-Carboxylic Acid And Salts Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT, CYP3A7 | PDE5A 681/4885KCNH2 808/4885 |
| US-20090156618-A1 | 1-(1- (2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino) - 1H-Pyrazolo [4,3-D] Pyrimidin-5-YL) Piperidine-4-Carboxylic acid and salts thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT, CYP3A7 | PDE5A 681/4885KCNH2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.